667 related articles for article (PubMed ID: 25425121)
21. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
Schiffmann R; Ries M; Blankenship D; Nicholls K; Mehta A; Clarke JT; Steiner RD; Beck M; Barshop BA; Rhead W; West M; Martin R; Amato D; Nair N; Huertas P
Genet Med; 2013 Dec; 15(12):983-9. PubMed ID: 23680766
[TBL] [Abstract][Full Text] [Related]
22. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
23. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.
Ramaswami U; Wendt S; Pintos-Morell G; Parini R; Whybra C; Leon Leal JA; Santus F; Beck M
Acta Paediatr; 2007 Jan; 96(1):122-7. PubMed ID: 17187618
[TBL] [Abstract][Full Text] [Related]
24. The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.
Khan A; Sirrs SM; Bichet DG; Morel CF; Tocoian A; Lan L; West ML;
Drugs R D; 2021 Dec; 21(4):385-397. PubMed ID: 34542871
[TBL] [Abstract][Full Text] [Related]
25. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.
Ripeau D; Amartino H; Cedrolla M; Urtiaga L; Urdaneta B; Cano M; Valdez R; Antongiovanni N; Masllorens F
Medicina (B Aires); 2017; 77(3):173-179. PubMed ID: 28643672
[TBL] [Abstract][Full Text] [Related]
26. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.
Schiffmann R; Goker-Alpan O; Holida M; Giraldo P; Barisoni L; Colvin RB; Jennette CJ; Maegawa G; Boyadjiev SA; Gonzalez D; Nicholls K; Tuffaha A; Atta MG; Rup B; Charney MR; Paz A; Szlaifer M; Alon S; Brill-Almon E; Chertkoff R; Hughes D
J Inherit Metab Dis; 2019 May; 42(3):534-544. PubMed ID: 30834538
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
[TBL] [Abstract][Full Text] [Related]
28. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey.
Ramaswami U; Parini R; Pintos-Morell G; Kalkum G; Kampmann C; Beck M;
Clin Genet; 2012 May; 81(5):485-90. PubMed ID: 21457233
[TBL] [Abstract][Full Text] [Related]
29. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
30. Agalsidase alfa long-term effect on left ventricular hypertrophy in Fabry disease.
Ferrari G; Kisinovsky I; Reisin R; Rozenfeld P; Neumann P; Finn V; Marchesoni C; Quieto P;
Medicina (B Aires); 2024; 84(3):516-525. PubMed ID: 38907966
[TBL] [Abstract][Full Text] [Related]
31. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.
Caballero L; Climent V; Hernández-Romero D; Quintanilla MA; de la Morena G; Marín F
Curr Med Chem; 2010; 17(16):1679-89. PubMed ID: 20345350
[TBL] [Abstract][Full Text] [Related]
32. Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease.
Hughes D; Gonzalez D; Maegawa G; Bernat JA; Holida M; Giraldo P; Atta MG; Chertkoff R; Alon S; Almon EB; Rocco R; Goker-Alpan O
Genet Med; 2023 Dec; 25(12):100968. PubMed ID: 37634127
[TBL] [Abstract][Full Text] [Related]
33. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
Schiffmann R; Ries M; Timmons M; Flaherty JT; Brady RO
Nephrol Dial Transplant; 2006 Feb; 21(2):345-54. PubMed ID: 16204287
[TBL] [Abstract][Full Text] [Related]
34. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
35. Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
Parini R; Pintos-Morell G; Hennermann JB; Hsu TR; Karabul N; Kalampoki V; Gurevich A; Ramaswami U;
Drug Des Devel Ther; 2020; 14():2149-2158. PubMed ID: 32581513
[TBL] [Abstract][Full Text] [Related]
36. Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.
Krämer J; Lenders M; Canaan-Kühl S; Nordbeck P; Üçeyler N; Blaschke D; Duning T; Reiermann S; Stypmann J; Brand SM; Gottschling T; Störk S; Wanner C; Sommer C; Brand E; Weidemann F
Nephrol Dial Transplant; 2018 Aug; 33(8):1362-1372. PubMed ID: 29186537
[TBL] [Abstract][Full Text] [Related]
37. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
[TBL] [Abstract][Full Text] [Related]
38. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
[TBL] [Abstract][Full Text] [Related]
39. [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].
Rivera Gallego A; López Rodríguez M; Barbado Hernández FJ; Barba Romero MA; García de Lorenzo Y Mateos A; Pintos Morelle G;
Med Clin (Barc); 2006 Oct; 127(13):481-4. PubMed ID: 17043001
[TBL] [Abstract][Full Text] [Related]
40. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
